Skip to main content

Table 3 Diagnostic performance for PCa of the most significant urine-gene expression signatures containing PCA3 gene, reported originally and validated in our cohort

From: Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers

Study Biomarkers Initial performance reported Performance validation (our cohort)
n total (T/C) SN (%) SP (%) AUC n total (T/C) SN (%) SP (%) AUC
Hessels et al., 2003 [4] PCA3 108 (24/84) 67 83 0.717 224 (151/73) 49 85 0.708
Hessels et al., 2007 [9] PCA3, TMPRSS2:ERG 108 (78/30) 73 52 - 224 (151/73) 48 86 0.708
Laxman et al., 2008 [10] PCA3, TMPRSS2:ERG, GOLPH2, SPINK1 234 (138/96) 66 76 0.758 224 (151/73) 72 64 0.719
Ouyang et al., 2009 [11] PCA3, AMACAR 92 (43/49) 81 53 - 224 (151/73) 48 85 0.707
Rigau et al., 2010 [12] PCA3, PSGR 215 (73/142) 77 60 0.73 224 (151/73) 62 71 0.708
Present study, 2015 HIST1H2BG, SPP1, ELF3 and PCA3 224 (151/73) 77 83 0.763 224 (151/73) 77 83 0.763
  1. Abbreviations: T Tumors, C Controls, SN Sensitivity, SP Specificity, AUC Area Under the Curve
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us